Tendencies in Oral Anticoagulant Usage for High-Risk Atrial Fibrillation Patients over Period of 5 Years and Correlation with Survivability

Activity: Talk or presentation types › Poster presentation

Description

Anticoagulant usage for high-risk non-valvular atrial fibrillation patients is the cornerstone for stroke prevention. A choice between K vitamin antagonists (mainly warfarin) and direct oral anticoagulants (DOAC) can be done. Aim of this study is to observe the tendencies of oral anticoagulant usage among high-risk atrial fibrillation patients over period of five years and its correlation with survivability.. A prospective longitudinal study was carried out November 2016- January 2022, including patients who were hospitalized in Pauls Stradins Clinical University Hospital or Riga East University Hospital. Questionnaire about demographic data, medical history, used medication was made at the enrollment and on follow-up after five years. All data were collected, statistical analysis (T-test, Spearman Corellation) was made using IBM SPSS Statistics 26.0.. Altogether 328 patients included, 5-year follow-up with 210 patients. On follow-up: males 58.1% (122), females 41.9% (88), average age at inclusion 71.0 years (SD 9.1). At enrollment (2016 – 2018), warfarin used 38.8% (81), DOAC – 35.4% (74) of which 23.0% (48) rivaroxaban and 12.4% (26) – dabigatran. Patients who did not use OAC for any reason (non-users) – 25.8% (54). At 5-year follow-up alive were 78.1% (164) of patients. At follow-up the DOAC used 75.4% (107) (rivaroxaban 50% (71), dabigatran 17.6% (25), apixaban 7.7%(11)), warfarin used 13.4% (19) and non-users - 11.3% (16). The average age for non-users was 72.6 years (SD 8.5 years), for OAC users - 70.4 (SD 9.17), Homogeneity of both groups were tested using T-test (p=0.14). At 5-year follow-up a statistically significant difference (Spearman Correlation, p=0.002) was between survival rate for non-users (63.0% (34)) and OAC users (83.2% (129)), favoring OAC users. No statistical difference between survivability was found comparing warfarin users to DOAC users (p=0.14).. A statistically significant difference (p=0.002) was found between the 5-year survivability comparing OAC users and non-users, favoring OAC users.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content